Neoadjuvant Short-term Intensive Intravesical Mitomycin C Regimen Compared with Weekly Schedule for Low-grade Recurrent Non–muscle-invasive Bladder Cancer: Preliminary Results of a Randomised Phase 2 Study-Reference-Cited by-同舟云学术

Neoadjuvant Short-term Intensive Intravesical Mitomycin C Regimen Compared with Weekly Schedule for Low-grade Recurrent Non–muscle-invasive Bladder Cancer: Preliminary Results of a Randomised Phase 2 Study

Published:2012-11 Issue:5 Volume:62 Page:797-802
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Colombo Renzo,Rocchini Lorenzo,Suardi Nazareno,Benigni Fabio,Colciago Giorgia,Bettiga Arianna,Pellucchi Federico,Maccagnano Carmen,Briganti Alberto,Salonia Andrea,Rigatti Patrizio,Montorsi Francesco

Publisher

Elsevier BV

Subject

Urology

Reference24 articles.

1. Short-schedule intravesical gemcitabine with ablative intent in recurrent Ta-T1, G1-G2, low- or intermediate-risk, transitional cell carcinoma of the bladder;Maffezzini;Eur Urol,2007

2. Superficial bladder cancer: the response of a marker tumour to a single intravesical instillation of epirubicin;Popert;Br J Urol,1994

3. Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response;van der Heijden;J Urol,2006

4. Phase II trials in Ta, T1 bladder cancer. The marker tumour concept;van der Meijden;Br J Urol,1996

5. Intravesical chemoresection with 4′-epi-doxorubicin in patients with superficial bladder tumors;Calais da Silva;Eur Urol,1988

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Deintensification of Treatment for Low-grade Bladder Tumors: A Collaborative Review by the International Bladder Cancer Group (IBCG);European Urology Oncology;2024-08

2. Re: Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients with Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study;European Urology;2023-10

3. Editorial Comment;Journal of Urology;2023-10

4. First-line Intravesical Chemotherapy for Non–muscle-invasive Bladder Cancer: Chimera or “Ne Plus Ultra”?;European Urology;2023-07

5. Reply to Benjamin Pradere, Giuseppe Basile, and Thomas Seisen’s Letter to the Editor re: Maria S. Lindgren, Eric Hansen, Nessn Azawi, Anna M. Nielsen, Lars Dyrskjøt, Jørgen B. Jensen. DaBlaCa-13 Study: Oncological Outcome of Short-term, Intensive Chemoresection with Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial. J Clin Oncol 2023;41:2,206–11;European Urology;2023-04